JP2013522231A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013522231A5 JP2013522231A5 JP2012557263A JP2012557263A JP2013522231A5 JP 2013522231 A5 JP2013522231 A5 JP 2013522231A5 JP 2012557263 A JP2012557263 A JP 2012557263A JP 2012557263 A JP2012557263 A JP 2012557263A JP 2013522231 A5 JP2013522231 A5 JP 2013522231A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- influenza virus
- immunizing
- reducing end
- rha
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 20
- 241000712461 unidentified influenza virus Species 0.000 claims 15
- 230000003053 immunization Effects 0.000 claims 12
- 238000000034 method Methods 0.000 claims 11
- 239000000203 mixture Substances 0.000 claims 11
- 239000002671 adjuvant Substances 0.000 claims 8
- 229910052799 carbon Inorganic materials 0.000 claims 6
- 125000003473 lipid group Chemical group 0.000 claims 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 4
- 150000001408 amides Chemical class 0.000 claims 4
- 150000002016 disaccharides Chemical class 0.000 claims 4
- 150000002148 esters Chemical class 0.000 claims 4
- 238000002347 injection Methods 0.000 claims 4
- 239000007924 injection Substances 0.000 claims 4
- 230000036039 immunity Effects 0.000 claims 3
- 238000002649 immunization Methods 0.000 claims 3
- 230000001681 protective effect Effects 0.000 claims 3
- 101710154606 Hemagglutinin Proteins 0.000 claims 2
- 101710093908 Outer capsid protein VP4 Proteins 0.000 claims 2
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 claims 2
- 101710176177 Protein A56 Proteins 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 2
- 125000000600 disaccharide group Chemical group 0.000 claims 2
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims 2
- 239000000185 hemagglutinin Substances 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 208000002979 Influenza in Birds Diseases 0.000 claims 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 206010064097 avian influenza Diseases 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- 206010022000 influenza Diseases 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 125000002889 tridecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000002948 undecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31310110P | 2010-03-11 | 2010-03-11 | |
| US61/313,101 | 2010-03-11 | ||
| PCT/US2011/027993 WO2011112871A1 (en) | 2010-03-11 | 2011-03-10 | Vaccines for pandemic influenza |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016037168A Division JP2016104815A (ja) | 2010-03-11 | 2016-02-29 | インフルエンザのためのワクチン |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013522231A JP2013522231A (ja) | 2013-06-13 |
| JP2013522231A5 true JP2013522231A5 (enExample) | 2014-04-24 |
Family
ID=44170437
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012557263A Pending JP2013522231A (ja) | 2010-03-11 | 2011-03-10 | インフルエンザのためのワクチン |
| JP2016037168A Pending JP2016104815A (ja) | 2010-03-11 | 2016-02-29 | インフルエンザのためのワクチン |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016037168A Pending JP2016104815A (ja) | 2010-03-11 | 2016-02-29 | インフルエンザのためのワクチン |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20110305748A1 (enExample) |
| EP (1) | EP2544718A1 (enExample) |
| JP (2) | JP2013522231A (enExample) |
| KR (1) | KR20130048208A (enExample) |
| CN (1) | CN102946900A (enExample) |
| AU (1) | AU2011224245B2 (enExample) |
| BR (1) | BR112012022939A2 (enExample) |
| CA (1) | CA2792369A1 (enExample) |
| EA (1) | EA201290897A1 (enExample) |
| MX (1) | MX2012010472A (enExample) |
| NZ (1) | NZ602217A (enExample) |
| SG (1) | SG183514A1 (enExample) |
| WO (1) | WO2011112871A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3632463A1 (en) | 2011-04-08 | 2020-04-08 | Immune Design Corp. | Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses |
| DK2811981T3 (da) * | 2012-02-07 | 2019-06-11 | Infectious Disease Res Inst | Forbedrede adjuvansformuleringer, der omfatter tlr4-agonister, og fremgangsmåder til anvendelse heraf |
| JP5944210B2 (ja) * | 2012-04-18 | 2016-07-05 | 一般財団法人化学及血清療法研究所 | 新型インフルエンザウイルス由来ヘマグルチニンタンパク質遺伝子が組み込まれたｂ５ｒ遺伝子欠損組換えワクシニアウイルス |
| JP2016532712A (ja) * | 2013-09-05 | 2016-10-20 | イミューン デザイン コーポレイション | 薬物中毒に対するワクチン組成物 |
| US9504743B2 (en) | 2013-09-25 | 2016-11-29 | Sequoia Sciences, Inc | Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections |
| US9149521B2 (en) | 2013-09-25 | 2015-10-06 | Sequoia Sciences, Inc. | Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections |
| US9149522B2 (en) | 2013-09-25 | 2015-10-06 | Sequoia Sciences, Inc. | Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections |
| US20150086592A1 (en) | 2013-09-25 | 2015-03-26 | Sequoia Sciences, Inc | Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections |
| CN111375055B (zh) * | 2020-02-20 | 2021-09-03 | 陈宛莎 | 一种2019-nCoV亚单位疫苗组合物及其免疫方法 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ199722A (en) | 1981-02-25 | 1985-12-13 | Genentech Inc | Dna transfer vector for expression of exogenous polypeptide in yeast;transformed yeast strain |
| US4876197A (en) | 1983-02-22 | 1989-10-24 | Chiron Corporation | Eukaryotic regulatable transcription |
| US4745051A (en) | 1983-05-27 | 1988-05-17 | The Texas A&M University System | Method for producing a recombinant baculovirus expression vector |
| EP0187840B1 (en) | 1984-07-20 | 1991-02-06 | Celltech Limited | Eucaryotic expression vectors |
| US5352449A (en) | 1986-05-30 | 1994-10-04 | Cambridge Biotech Corporation | Vaccine comprising recombinant feline leukemia antigen and saponin adjuvant |
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| ATE115862T1 (de) | 1989-02-04 | 1995-01-15 | Akzo Nobel Nv | Tocole als impfstoffadjuvans. |
| ZA929870B (en) | 1991-12-23 | 1993-08-18 | Duphar Int Res | Adjuvants |
| US6022726A (en) | 1992-02-03 | 2000-02-08 | Palese; Peter | Genetically engineered attenuated viruses |
| US5273965A (en) | 1992-07-02 | 1993-12-28 | Cambridge Biotech Corporation | Methods for enhancing drug delivery with modified saponins |
| WO1994001133A1 (en) | 1992-07-08 | 1994-01-20 | Schering Corporation | Use of gm-csf as a vaccine adjuvant |
| US5762939A (en) | 1993-09-13 | 1998-06-09 | Mg-Pmc, Llc | Method for producing influenza hemagglutinin multivalent vaccines using baculovirus |
| US5961970A (en) | 1993-10-29 | 1999-10-05 | Pharmos Corporation | Submicron emulsions as vaccine adjuvants |
| DE9319879U1 (de) | 1993-12-23 | 1994-03-17 | Ems-Inventa AG, Zürich | Sequentiell Coextrudierte Kühlflüssigkeitsleitung |
| GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
| US5718904A (en) | 1995-06-02 | 1998-02-17 | American Home Products Corporation | Adjuvants for viral vaccines |
| US20030045492A1 (en) | 1997-08-13 | 2003-03-06 | Tang De-Chu C. | Vaccination by topical application of recombinant vectors |
| GB9809666D0 (en) | 1998-05-06 | 1998-07-01 | Isis Innovation | Modified viruses |
| HK1039072A1 (zh) | 1998-05-07 | 2002-04-12 | 科里克萨有限公司 | 佐剂组合物及其使用方法 |
| US6103526A (en) | 1998-10-08 | 2000-08-15 | Protein Sciences Corporation | Spodoptera frugiperda single cell suspension cell line in serum-free media, methods of producing and using |
| AU769539B2 (en) | 1999-01-29 | 2004-01-29 | Zoetis Services Llc | Adjuvants for use in vaccines |
| MY134424A (en) | 2001-05-30 | 2007-12-31 | Saechsisches Serumwerk | Stable influenza virus preparations with low or no amount of thiomersal |
| US8592197B2 (en) | 2003-07-11 | 2013-11-26 | Novavax, Inc. | Functional influenza virus-like particles (VLPs) |
| AU2005248361B2 (en) | 2004-05-18 | 2010-03-11 | Vical Incorporated | Influenza virus vaccine composition and methods of use |
| DK1773384T3 (en) | 2004-06-01 | 2015-11-23 | Us Agriculture | GM swine influenza virus and uses thereof |
| US8137676B2 (en) | 2005-02-15 | 2012-03-20 | Mount Sinai School Of Medicine | Genetically engineered equine influenza virus and uses thereof |
| PL2043682T3 (pl) * | 2006-07-17 | 2014-09-30 | Glaxosmithkline Biologicals Sa | Szczepionka przeciw grypie |
| US20090181078A1 (en) * | 2006-09-26 | 2009-07-16 | Infectious Disease Research Institute | Vaccine composition containing synthetic adjuvant |
| PT2484375T (pt) | 2006-09-26 | 2018-07-09 | Infectious Disease Res Inst | Composição para vacina contendo adjuvante sintético |
| US8202967B2 (en) * | 2006-10-27 | 2012-06-19 | Boehringer Ingelheim Vetmedica, Inc. | H5 proteins, nucleic acid molecules and vectors encoding for those, and their medicinal use |
| JP2007314538A (ja) * | 2007-05-23 | 2007-12-06 | Protein Sciences | インフルエンザ血球凝集素多価ワクチンの製造方法 |
| US8563523B2 (en) | 2007-09-07 | 2013-10-22 | University Of Georgia Research Foundation, Inc. | Synthetic lipid A derivative |
| WO2009092038A1 (en) | 2008-01-16 | 2009-07-23 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Influenza dna vaccination and methods of use thereof |
| HRP20161585T1 (hr) | 2009-06-05 | 2016-12-30 | Infectious Disease Research Institute | Sintetski glukopiranozilni lipidi kao adjuvansi i cjepivni pripravci koji ih sadrže |
-
2011
- 2011-03-10 SG SG2012063509A patent/SG183514A1/en unknown
- 2011-03-10 MX MX2012010472A patent/MX2012010472A/es unknown
- 2011-03-10 CN CN2011800232817A patent/CN102946900A/zh active Pending
- 2011-03-10 WO PCT/US2011/027993 patent/WO2011112871A1/en not_active Ceased
- 2011-03-10 BR BR112012022939A patent/BR112012022939A2/pt not_active IP Right Cessation
- 2011-03-10 AU AU2011224245A patent/AU2011224245B2/en not_active Ceased
- 2011-03-10 NZ NZ602217A patent/NZ602217A/en not_active IP Right Cessation
- 2011-03-10 EA EA201290897A patent/EA201290897A1/ru unknown
- 2011-03-10 US US13/045,245 patent/US20110305748A1/en not_active Abandoned
- 2011-03-10 CA CA2792369A patent/CA2792369A1/en not_active Abandoned
- 2011-03-10 EP EP11715321A patent/EP2544718A1/en not_active Withdrawn
- 2011-03-10 KR KR1020127025971A patent/KR20130048208A/ko not_active Ceased
- 2011-03-10 JP JP2012557263A patent/JP2013522231A/ja active Pending
-
2016
- 2016-02-29 JP JP2016037168A patent/JP2016104815A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013522231A5 (enExample) | ||
| Goff et al. | Synthetic Toll-like receptor 4 (TLR4) and TLR7 ligands as influenza virus vaccine adjuvants induce rapid, sustained, and broadly protective responses | |
| JP6185548B2 (ja) | インフルエンザワクチンの製造方法 | |
| HRP20190876T1 (hr) | Novi adjuvantirani pripravci | |
| Quan et al. | Progress in developing virus-like particle influenza vaccines | |
| Isakova-Sivak et al. | Influenza vaccine: Progress in a vaccine that elicits a broad immune response | |
| RU2015132962A (ru) | Иммуногенные композиции на основе вируса гриппа и их применение | |
| WO2010036948A3 (en) | Dna vaccine against influenza virus and prime boost method | |
| Noh et al. | Influenza vaccines: unmet needs and recent developments | |
| JP2009539965A5 (enExample) | ||
| IL321503A (en) | Recombinant virus, composition comprising the same, and uses thereof | |
| Chua et al. | Inactivated influenza vaccine that provides rapid, innate-immune-system-mediated protection and subsequent long-term adaptive immunity | |
| Schotsaert et al. | Inactivated influenza virus vaccines: the future of TIV and QIV | |
| RU2011117167A (ru) | Вакцинная композиция против гриппа | |
| US10548965B2 (en) | Synergistic co-administration of computationally optimized broadly reactive antigens for human and avian H5N1 influenza | |
| US10925957B2 (en) | Synergistic co-administration of computationally optimized broadly reactive antigens for H1N1 influenza | |
| Quan et al. | Progress in the development of virus-like particle vaccines against respiratory viruses | |
| RU2016111704A (ru) | Производные дезоксинойиримицина и способы их применения | |
| BRPI0918806A2 (pt) | composição compreendendo quitosana para administração ocular de vaninas em aves | |
| BR112012022939A2 (pt) | composição farmacêutica para uso em um método de imunização de um indivíduo em necessidade do mesmo contra um vírus influenza | |
| CN106999570B (zh) | 含至少一种流感病毒的中和性结合分子的佐剂组合物及含该佐剂组合物的疫苗组合物 | |
| JP2016534062A5 (enExample) | ||
| RU2014140168A (ru) | Улучшенная вакцинация против гриппа | |
| JP2009518410A5 (enExample) | ||
| JP2016520077A5 (enExample) |